Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY22 results · Jan–Mar 2022
Bliss GVS Pharma reported revenue from operations of ₹167.06 crore (up 26.5% from Q4 FY21) and net profit of ₹23.47 crore (up 187.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 167.06 | 132.05 | +26.5% | 216.26 | −22.7% |
| Other income | 12.19 | 6.33 | +92.7% | 6.04 | +101.9% |
| Total income | 179.25 | 138.38 | +29.5% | 222.29 | −19.4% |
| Profit before tax | 26.45 | 16.58 | +59.5% | (38.86) | Turned profit |
| Net profit for the period | 23.47 | 8.15 | +187.8% | (48.53) | Turned profit |
| Attributable to shareholders of the company | 19.63 | 6.24 | +214.5% | (50.11) | Turned profit |
| EPS, basic (₹) | 1.90 | 0.61 | +211.5% | (4.83) | Turned profit |
| Net margin (%) | 14.0 | 6.2 | -22.4 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 138.30 | 105.23 | +31.4% | 190.60 | −27.4% |
| Other income | 12.44 | 4.30 | +189.3% | 6.31 | +97.1% |
| Total income | 150.74 | 109.53 | +37.6% | 196.91 | −23.4% |
| Profit before tax | 16.54 | 14.07 | +17.5% | 36.41 | −54.6% |
| Net profit for the period | 9.47 | 9.16 | +3.4% | 27.17 | −65.1% |
| EPS, basic (₹) | 1.85 | 0.89 | +107.9% | 2.62 | −29.4% |
| Net margin (%) | 6.8 | 8.7 | 14.3 |
Consolidated
- Filed with BSE
- 02 May 2022, 14:31 IST
- Board meeting
- 30 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2022, 14:31 IST
- Board meeting
- 30 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE